Claims for Patent: 7,799,336

Summary for Patent: 7,799,336

Title:	Hypotensive lipid-containing biodegradable intraocular implants and related methods
Abstract:	Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Inventor(s):	Hughes; Patrick M. (Alsio Viejo, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/837,260
Patent Claims:	1. A biodegradable intraocular implant comprising: a prostamide component and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of a therapeutically effective amount of the prostamide component for at least about one week after the implant is placed in an eye. 2. The implant of claim 1, wherein the prostamide component comprises a single type of a prostamide derivative. 3. The implant of claim 1, wherein the prostamide component is dispersed within the biodegradable polymer matrix. 4. The implant of claim 1, wherein the prostamide component comprises bimatoprost provided in an amount of about 0.1% to about 90% by weight of the implant. 5. The implant of claim 1, wherein the prostamide component comprises a compound having the formula (I) ##STR00008## wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be interrupted by one or more oxide radicals and substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups wherein said alkyl radical comprises from one to six carbon atoms; B is a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals having from four to ten carbon atoms wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms; X is a radical selected from the group consisting of --OR.sup.4 and --N(R.sup.4).sub.2 wherein R.sup.4 is selected from the group consisting of hydrogen, a lower alkyl radical having from one to six carbon atoms, ##STR00009## wherein R.sup.5 is a lower alkyl radical having from one to six carbon atoms; Z is .dbd.O or represents 2 hydrogen radicals; one of R.sub.1 and R.sub.2 is .dbd.O, --OH or a --O(CO)R.sub.6 group, and the other one is --OH or --O(CO)R.sub.6, or R.sub.1 is .dbd.O and R.sub.2 is H, wherein R.sub.6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.mR.sub.7 wherein m is 0 or an integer of from 1 to 10, and R.sub.7 is cycloalkyl radical, having from three to seven carbon atoms, or a hydrocarbyl aryl or heteroaryl radical, as defined above, or a pharmaceutically-acceptable salt thereof, provided, however, that when B is not substituted with a pendant heteroatom-containing radical, and Z is .dbd.O, then X is not --OR.sup.4. 6. The implant of claim 1, wherein the matrix comprises a mixture of two different biodegradable polymers, each polymer selected from the group consisting of polylactic acid, polyglycolic acid, polylactide-co-glycolide, derivatives thereof, and mixtures thereof. 7. The implant of claim 6, wherein the matrix comprises a mixture of two different polylactic acids. 8. The implant of claim 6, wherein the matrix comprises a mixture of a polylactic acid and a polylactide-co-glycolide. 9. The implant of claim 1, wherein the matrix comprises a mixture of different biodegradable polymers, each biodegradable polymer having a different inherent viscosity. 10. The implant of claim 1, wherein the matrix comprises a mixture of different biodegradable polymers, each polymer having a different molecular weight. 11. The implant of claim 1, wherein the matrix releases drug at a rate effective to sustain release of an amount of the prostamide component from the implant for more than one month from the time the implant is placed in the vitreous of the eye. 12. The implant of claim 1, wherein the therapeutically effective amount of the prostamide component is an amount effective to stimulate aqueous humor outflow in the eye in which the implant is placed. 13. The implant of claim 1, further comprising a prostaglandin analogue. 14. The implant of claim 13 wherein the prostaglandin analog is unoprostone. 15. The implant of claim 1, further comprising an intraocular pressure lowering drug other than a prostamide derivative. 16. The implant of claim 1, wherein the implant is structured to be placed in the vitreous of the eye. 17. The implant of claim 1 which is formed by an extrusion process.